Abstract:Purpose Salvage interstitial rectal brachytherapy (SIRB) is a promising therapeutic modality for patients facing recurrent anorectal malignancies. This study undertakes a detailed examination of patients who underwent SIRB, highlighting the efficacy and response to treatment. Additionally, we present our findings on potential toxicities, providing valuable information to enhance the understanding of the safety profile of interstitial brachytherapy. Materials and Methods A retrospective analysis was conducted, encompassing all patients diagnosed with locally recurrent anal, rectal, and colon cancer situated within the pelvic cavity and treated with 3D image-guided interstitial brachytherapy between January 2018 and December 2023. Data collection included patient demographics, prior treatment history, brachytherapy dosimetry, post-SIRB treatments, and toxicity outcomes. Descriptive statistics were reported using median values with inter-quartile range or absolute count data. Cumulative incidence of failure was then analyzed. Results Thirteen patients (9 adenocarcinoma and 4 squamous cell carcinoma) with a median follow-up of 15.3 (10.3-21.6) months post SIRB were identified. Four of these received EBRT boost. Median clinical target volume (CTV) was 25.9 (18.8-75.2) cc. Median SIRB dose was 17.3 (14-18.5) Gy in 3(2-3) and 24 (15-42) Gy in 5(3-6) fractions with or without EBRT boost, respectively. Total minimum dose to the 90% of CTV (CTVD90) and 98% of GTV (GTVD98) in 2Gy equivalents (EQD2) were 80.1 (76.6-100.4) Gy and 97.3 (79.4-111.5) Gy, respectively, for the entire cohort. Twelve patients demonstrated complete response (CR) based on radiological (n=9), clinical (n=6), and/or biochemical (n=3) assessments. One patient did not demonstrate CR and had local in-field recurrence within 10 months post SIRB. Five and 8 patients developed regional out-of-field and distant recurrence, with median time to recurrence 12.9 months (6.2-16.5 months) and 15.3 months (4.8-40.8 months), respectively. Grade ≥2 toxicity was observed in 8 patients including 3 G2 toxicities (rectal bleeding, vaginal stricture, and pelvic pain) and 5 G3/4 toxicities (necrotic abscess, ulceration, ureteric obstruction, uretero-vaginal and cutaneous fistula). Patients who developed necrosis had a larger median CTV volume (89.4 cc versus 16.8cc, p=0.08) and higher volume that received 200% of dose (V200: 14.8 cc versus 3.4 cc, p=.41), compared to those that did not develop necrosis. Ten patients were still alive at last available follow-up. Conclusions Salvage interstitial rectal brachytherapy (SIRB) is an effective treatment modality for addressing locally recurrent anorectal cancer in the pelvis. SIRB offers robust local control with a favorable toxicity profile. Establishment of formalized treatment dose prescriptions and dosimetric parameters is imperative to enhance the consistency and reproducibility of this therapeutic approach. Future endeavors should prioritize prospective studies to gather comprehensive data, further refining and standardizing the implementation of SIRB in the clinical setting.

PO0322: Salvage Interstitial Rectal Brachytherapy: A Single Institution Retrospective Analysis

Salvage Low Dose Rate Brachytherapy For Recurrent Prostate Cancer After External Beam Radiotherapy: Results From A Single Institution With Focus On Toxicity And Functional Outcomes

Salvage interstitial brachytherapy for treatment of recurrent endometrial cancers in the vagina: Seven-year single institution experience and review of second recurrence patterns

Long-term outcomes for patients with radiorecurrent prostate cancer treated with salvage combination IMRT and brachytherapy.

Efficacy and safety of stereotactic ablative brachytherapy (SABT) as salvage treatment for sacral region local recurrent rectal cancer: a multicenter retrospective study

Surg-53. Long Term Follow-Up Of Resection Plus Cesium-131 Brachytherapy For Previously Irradiated Recurrent Brain Metastases

Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes

Outcome of intraoperative brachytherapy as a salvage treatment for locally recurrent rectal cancer

Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy

Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical Prostatectomy

Salvage brachytherapy for second ipsilateral breast tumor event: Relating dosimetric analysis to late side effects

Image-guided interstitial brachytherapy for recurrent cervical cancer after radiotherapy: A single institution experience

Salvage 125I Brachytherapy for Liver Metastases of Colorectal Cancer in Anatomically Challenging Locations after Failure of Systemic Chemotherapy-a Retrospective Study.

A Dosimetric Analysis of Preoperative Intensity-modulated and Image-guided Radiation Therapy with and without Simultaneous Integrated Boost for Locally Advanced Rectal Cancer.

The Use of Re-irradiation in Locally Recurrent, Non-metastatic Rectal Cancer

Salvage low-dose-rate brachytherapy for locally recurrent prostate cancer after definitive irradiation

A multi-centre retrospective study of long-term outcomes of spinal re-irradiation with SABR

Safety and efficacy of intraoperative iodine-125 seed implantation brachytherapy for rectal cancer patients: A prospective clinical research.

Brachytherapy is an Effective and Safe Salvage Option for Re-Irradiation in Recurrent Glioblastoma (rgbm): A Systematic Review.

Efficacy and safety of 3-dimensional printing noncoplanar template (3D-PNCT)-assisted high-dose-rate interstitial brachytherapy (HDR-ISBT) for reirradiation of recurrent cervical cancer: a prospective cohort

Clinical outcomes after salvage external beam radiotherapy combined with interstitial brachytherapy for locally advanced, recurrent endometrial cancer